

ErlySign achieves CDSCO approval for clinical trials of oral cancer detection technology

08 April 2024 | News

Company secures patents for oral cancer detection kit in India and the US



ErlySign, a biotech startup located in Nagpur, has announced a significant milestone in the fight against cancer with approval from the Central Drugs Standard Control Organisation (CDSCO) for its active salivary biomarker study designed for early cancer detection.

Following a comprehensive year-long investigation and based on in-house validation data of 150 test samples, CDSCO has granted permission to ErlySign to proceed with large-scale clinical trials. Notably, during the initial studies, the active salivary biomarker study showcased remarkable performance, demonstrating a sensitivity of 98% and an unparalleled specificity of 100%.

The proprietary technology promises to revolutionise cancer detection through its advanced approach. With patents secured in both the United States (US) and India for their oral cancer detection kit, ErlySign's commitment to innovation is evident. This innovation streamlines the testing process, allowing multiple tests to be processed within a mere 15-20 minutes.

Moreover, the company's dedication to advancing cancer diagnostics extends to its lung cancer detection kit, for which a patent is currently pending. This pending patent underscores ERLYSIGN's ongoing efforts to expand its innovative contributions to cancer detection, aiming to provide cutting-edge solutions to healthcare challenges.

ERLYSIGN's dedication to advancing cancer detection technology is further exemplified by its recent developments, including the launch of an automated multi-sample reader for its oral cancer detection kit. This innovation streamlines the testing process, allowing multiple tests to be processed within a mere 15-20 minutes.